Sanofi’s Cablivi cleared for rare bleeding disorder

Patients with the rare clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP) have gained a new treatment option in Europe with the approval of Sanofi’s Cablivi.Original Article